Nucleic Acid Testing Market

Nucleic Acid Testing Market - Trends, Outlook, and
Opportunity Analysis, 2018-2026
Nucleic acid testing (NAT) or nucleic acid amplification test (NAAT) is one of the advanced
diagnostic test increasingly gaining traction over conventional culture methods, owing to high
efficiency and accuracy. Furthermore, nucleic acid testing has potential application in various
life threating diseases including cancer, infectious disease, genetic and mitochondrial disorders,
and also in development of personalized and precision medicine. NAT is an efficient diagnostic
method, which significantly reduces the procedural time and consumption of reagents.
Moreover, nucleic acid testing is increasingly being used for screening blood donation samples
to reduce the risk of transfusion transmitted infections (TTIs), thus aiding in growth of the
nucleic acid testing market.
Request PDF Brochure Of Research Report:
Nucleic Acid Testing Market – Driver
Nucleic acid tests are extensively used for screening and diagnosis of various infectious diseases.
Moreover, growing prevalence of infectious diseases and management of epidemics of new
diseases has led to increasing demand for advanced diagnostic tests such as nucleic acid testing.
For instance, according to the World Health Organization (WHO), in 2015, around 32,000
estimated deaths from tuberculosis and around 3, 23,000 new cases of TB were registered in
the European region. Furthermore, according to the Centers for Disease Control and Prevention
(CDC), around 5,251 deaths due to influenza infection were registered in 2015, in the U.S.
According to the National Ambulatory Medical Care Survey: 2015 data findings, 16.8 million
visits to physician offices for infectious and parasitic diseases were registered in the U.S.
Nucleic acid testing (NAT) enables to examine various changes in gene sequence and copy
number, and provides information regarding disease recurrence and possible condition of patient
to likely respond to a particular treatment. Moreover, NAT can identify, which patient have
undergone inherited mutations, which eventually helps to identify whether the patient is at
increased risk of developing cancer or not. Increasing incidence of cancer in various
geographical areas is a major driving factor for growing adoption of nucleic acid testing. For
instance, according to the Cancer Atlas: 2017, there were an estimated 14.1 million new cancer
cases in 2012. Moreover, India, China, and other East and Central Asian countries accounted for
nearly half of world’s new cancer cases and deaths, in 2017. Furthermore, according to the
same source, by 2025, there will be an estimated 19.3 million new cancer cases and 11.4
million cancer deaths, in less developed regions.
Moreover, research funding by various government and private organizations for cancer
treatment and increasing adoption of molecular and nucleic acid testing in cancer research
programs, to detect molecular genetic changes in single or multiple sequence of DNA or
mutations is expected to aid in growth of the nucleic acid testing market, in the near future. In
2016, National Cancer Institute (NCI) invested US$ 3.9 billion for cancer research activities,
which accounts for 70.8% of overall NCI 2016 budget. Among which NCI invested around US$
533 million on cancer detection and diagnostic research activities. Moreover, in 2016, NCI
allocated 40.4% of its funds for Research Project Grants (RPGs). Furthermore, in 2017, NCI
budget increased by US$ 454 million (8.7%) from previous year (2016) for research activities.
Report includes chapters which deeply display the following deliverable about industry :
• Nucleic Acid Testing Market Research Objective and Assumption
• Nucleic Acid Testing Market Purview - Report Description, Executive Summary, and Coherent
Opportunity Map (COM)
• Nucleic Acid Testing Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Nucleic Acid Testing Market, By Regions
• Nucleic Acid Testing Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Nucleic Acid Testing Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Nucleic Acid Testing Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Nucleic Acid Testing Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Nucleic Acid Testing Market – Restraint
The inability or difficulty of nucleic acid testing in obtaining quantitative results from a large
pool of clinical sample, difficulty of using NAT test for susceptibility testing, and higher cost of
nucleic acid testing devices is expected to hamper growth of the nucleic acid testing market.
According to the data published in Asian Journal of Transfusion Science, in February 2014,
NAT is highly sensitive and advanced technique, however, it is associated with high cost and
requires dedicated infrastructure facility, equipment, consumables, and technical expertise.
Browse Complete Report For More Information @
Nucleic Acid Testing Market - Regional Analysis
Geographically, global nucleic acid testing market is segmented into North America, Latin
America, Europe, Middle East, Asia Pacific, and Africa. North America holds dominant position
in nucleic acid testing market, followed by Europe. This is owing to increasing research and
development studies by various government and pharmaceutical organizations in infectious
disease and cancer diagnosis in North America. For instance, in January 2018, University of
Glasgow-led project received US$ 1.85 million funding, which is a part of Global Challenges
Research Fund (GCRF). This project will develop new tests for parasitic diseases and rapid
testing in remote locations to help enable rapid diagnosis, and rapid treatment of infectious
disease. Furthermore, high prevalence and awareness of cancer among people, in turn opting
for early detection of cancer, is expected to aid in growth of the nucleic acid testing market in
this region. For instance, according to American Cancer Society, data findings, North America
registered higher incidence of cancer in children compared to any other region, in 2012.
Moreover, North America accounted for 13.1% of total estimated cases of cancer, in 2012,
globally, according to the same source.
Asia Pacific is expected to witness fastest growth in the nucleic acid testing market over the
forecast period. This is due to growing demand for efficient and quick diagnostic testing and
increasing focus of major market players to expand their geographical reach in this region. For
instance, in March 2013, Qiagen N.V. launched its careHPV test in China. careHPV is molecular
diagnostic test designed to screen for high risk human papillomavirus (HPV) for low-resource
settings such as areas lacking electricity, water or laboratories. Qiagen also gained the approval
from China's State Food and Drug Administration (SFDA) for careHPV in 2012.
Nucleic Acid Testing Market – Competitive Analysis
Key market players in nucleic acid testing market are Abbott Laboratories, Beckman Coulter,
Inc., Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories, Inc., F. HoffmannLa Roche Ltd., Grifols, S.A., Illumina, Inc., Novartis Ag, Qiagen N.V., Quest Diagnostics
Incorporated, Siemens Ag, and Tecan Group Ltd., among others. Players in the market are
focusing on inorganic growth strategies, in order to enhance its market share and remain
competitive in the market. For instance, in January 2017, Grifols, S.A. acquired the NAT
(Nucleic Acid Testing) donor screening unit from Hologic, Inc. for US$ 1,850 million. The
acquisition enabled Grifols to strengthen its position in transfusion medicine through NAT
To Get Instant Access, Purchase Report Here @
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]

Nucleic acid testing (NAT) or nucleic acid amplification test (NAAT) is one of the advanced diagnostic test increasingly gaining traction over conventional culture methods, owing to high efficiency and accuracy.